Core Viewpoint - The article highlights the successful development of ASC30, a long-acting subcutaneous formulation of a small molecule GLP-1 receptor agonist by the company, which shows promise for quarterly dosing in obesity management, addressing an unmet need in long-term weight management [2][5]. Group 1: Product Development - ASC30 is the first and currently the only investigational small molecule GLP-1 receptor agonist that can be developed as an oral tablet taken once daily or a subcutaneous formulation administered monthly or quarterly [5]. - The clinical study in the U.S. demonstrated a 75-day half-life for ASC30, indicating its potential for less frequent dosing [2]. - The treatment showed good tolerability with only mild gastrointestinal reactions, which may enhance patient compliance and quality of life [2]. Group 2: Company Overview - The company focuses on innovative therapies for chronic diseases, particularly in the development of small molecule drugs aimed at sustainable weight control [6]. - ASC30 is a new chemical entity (NCE) with compound patent protection in the U.S. and globally until 2044, excluding any patent extensions [5].
速递｜每三个月只要1针！歌礼制药推出超长效减重GLP-1药物